BioRender 图标

Neuroblastoma (SH-SY5Y, differentiated 2)

Neuroblastoma (SH-SY5Y, differentiated 2) - Editable icon of Neuroblastoma (SH-SY5Y, differentiated 2)
[{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6991/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6991/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6990/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6990/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698f/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698f/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698e/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698e/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698d/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698d/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698c/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698c/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698b/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698b/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a698a/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a698a/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6989/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6989/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6988/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6988/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6987/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6987/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6986/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6986/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6985/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6985/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6984/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6984/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6983/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6983/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6982/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6982/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6981/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6981/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6980/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6980/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697f/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697f/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697e/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697e/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697d/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697d/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697c/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697c/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697b/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697b/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a697a/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a697a/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6979/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6979/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6978/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6978/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6977/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6977/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6976/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6976/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6975/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6975/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6974/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6974/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6973/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6973/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6972/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6972/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6971/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6971/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6970/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6970/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696f/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696f/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696e/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696e/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696d/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696d/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696c/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696c/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696b/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696b/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a696a/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a696a/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6969/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6969/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6968/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6968/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6967/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6967/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6966/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6966/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6965/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6965/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6964/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6964/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6963/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6963/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6962/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6962/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6961/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6961/630635d07c75bb00281a68f9.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637b67c75bb00281a6960/630635d07c75bb00281a68f9.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637b67c75bb00281a6960/630635d07c75bb00281a68f9.png"}]
使用此图标 – 免费
注册无需信用卡。

此图标可在 BioRender 中完全编辑

  • 添加文本、形状及其他图标
  • 搜索 50,000 多种科学准确的图标
  • 重新着色并重新排列每一个图标、线条和标签
  • 导出或分享以满足任何使用需求
Scientist Avatars

加入 400 多万名科学家 的行列,制作可直接用于发表的图表

从图标到成品图表,只需几分钟

  • 搜索 来自 50,000 多个科学准确、经同行评审的图标
  • 自定义 添加标签、形状和更多图标——一切皆可完全编辑
  • 导出 或与协作者分享您的图表
    ‍

图标不合适?探索更多内容。

搜索涵盖 30 多个生命科学领域的 50,000 多个图标。

search icon
arrow-right
neuroblastoma,SH-sy5y,SK-N-SH,parkinson,neurogenesis,differentiated,differentiation,n type,SH-sy5y
查看更多

尝试使用同义词,或注册以在应用中请求图标。

图像类型

Neuroblastoma (SH-SY5Y, differentiated 2) icon JPEG

Neuroblastoma (SH-SY5Y, differentiated 2) icon PNG

Neuroblastoma (SH-SY5Y, differentiated 2) icon SVG

Neuroblastoma (SH-SY5Y, differentiated 2) icon GIF

BioRender 图标常见问题解答

How are scientists using the Neuroblastoma (SH-SY5Y, differentiated 2) icon in their work?

BioRender users often use the Neuroblastoma (SH-SY5Y, differentiated 2) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

我可以在 BioRender 图表或科学插图中使用此图标吗?

Yes, the Neuroblastoma (SH-SY5Y, differentiated 2) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Neuroblastoma (SH-SY5Y, differentiated 2) icon customizable in BioRender?

Most icons in BioRender, including the Neuroblastoma (SH-SY5Y, differentiated 2) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Neuroblastoma (SH-SY5Y, differentiated 2) icon for publication or presentations?

Yes, figures containing the Neuroblastoma (SH-SY5Y, differentiated 2) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Neuroblastoma (SH-SY5Y, differentiated 2) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Neuroblastoma (SH-SY5Y, differentiated 2) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

什么是 BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Neuroblastoma (SH-SY5Y, differentiated 2) icon along with our library of more than 30,000 life science icons.

在 BioRender 中使用此图标

立即开始制作专业的科学图表
antibody elements3D Phospholipid illustration

正在寻找科学内容?

浏览超过 5 万个经同行评审、易于使用且免费的图标和模板。

立即寻找您的专属素材
x icon